I agree that this site is using cookies. You can find further informations here.
X
Caponigro, F.
54  results:
Search for persons X
?
1

Management of recurrent nasopharyngeal carcinoma: current p..:

Perri, F ; Della Vittoria Scarpati, G ; Caponigro, F...
OncoTargets and Therapy.  12 (2019)  - p. 1583-1591 , 2019
Link: https://doi.org/10.2147/..
 
?
2

Afatinib versus methotrexate in older patients with second-..:

Clement, P.M. ; Gauler, T. ; Machiels, J.P....
Annals of Oncology.  27 (2016)  8 - p. 1585-1593 , 2016
Link: https://doi.org/10.1093/..
 
?
3

OC-005: Afatinib versus methotrexate in recurrent/metastati..:

Clement, P. ; Gauler, T. ; Machiels, J.P.H....
Radiotherapy and Oncology.  114 (2015)  - p. 7-8 , 2015
Link: https://doi.org/10.1016/..
 
?
4

Electrochemotherapy, a novel integrated approach to the loc..:

Longo, F. ; Perri, F. ; Aversa, C....
European Journal of Surgical Oncology (EJSO).  38 (2012)  10 - p. 1007 , 2012
Link: https://doi.org/10.1016/..
 
?
5

583 Induction Chemotherapy with Docetaxel, Cisplatin and Ca..:

Perri, F. ; Muto, P. ; Schiavone, C....
European Journal of Cancer.  48 (2012)  - p. 178-179 , 2012
Link: https://doi.org/10.1016/..
 
?
6

An EORTC phase I study of Bortezomib in combination with ox..:

Caponigro, F. ; Lacombe, D. ; Twelves, C....
European Journal of Cancer.  45 (2009)  1 - p. 48-55 , 2009
Link: https://doi.org/10.1016/..
 
?
7

Phase I dose-escalation study of brostallicin, a minor groo..:

Caponigro, F. ; Lorusso, D. ; Fornari, G....
Cancer Chemotherapy and Pharmacology.  66 (2009)  2 - p. 389-394 , 2009
Link: https://doi.org/10.1007/..
 
?
8

715 POSTER Phase I dose-escalation study of brostallicin in..:

Lorusso, D. ; Fornari, G. ; Caponigro, F....
European Journal of Cancer Supplements.  5 (2007)  4 - p. 111-112 , 2007
Link: https://doi.org/10.1016/..
 
?
9

Multicentre EORTC study 16997: Feasibility and phase II tri..:

Theodore, C. ; Geoffrois, L. ; Vermorken, J.B....
European Journal of Cancer.  41 (2005)  8 - p. 1150-1157 , 2005
Link: https://doi.org/10.1016/..
 
?
10

Phase II study of XR 5000 (DACA), an inhibitor of topoisome..:

Dittrich, C ; Coudert, B ; Paz-Ares, L...
European Journal of Cancer.  39 (2003)  3 - p. 330-334 , 2003
Link: https://doi.org/10.1016/..
 
?
11

Phase II study of XR 5000, an inhibitor of topoisomerases I..:

Caponigro, F ; Dittrich, C ; Sorensen, J.B...
European Journal of Cancer.  38 (2002)  1 - p. 70-74 , 2002
Link: https://doi.org/10.1016/..
 
?
12

Patient preference and pharmacokinetics of oral modulated U..:

Borner, M.M ; Schöffski, P ; de Wit, R...
European Journal of Cancer.  38 (2002)  3 - p. 349-358 , 2002
Link: https://doi.org/10.1016/..
 
?
13

A phase II randomized study of cisplatin (CDDP), raltitrexe..:

Caponigro, F. ; De Rosa, P. ; Rosati, G....
European Journal of Cancer.  37 (2001)  - p. S105-S106 , 2001
Link: https://doi.org/10.1016/..
 
?
14

A phase II trial of cisplatin, methotrexate, levofolinic ac..:

Caponigro, F. ; Comella, P. ; Marcolin, P....
International Journal of Oral and Maxillofacial Surgery.  29 (2000)  3 - p. 232-234 , 2000
Link: https://doi.org/10.1034/..
 
?
15

Docetaxel (DTX) + cisplatin (CDDP) in locally advanced or m..:

Caponigro, F. ; De Lucia, L. ; Biglietto, M....
European Journal of Cancer.  35 (1999)  - p. S168 , 1999
Link: https://doi.org/10.1016/..
 
1-15